HomeComparePROC vs NOBL

PROC vs NOBL: Dividend Comparison 2026

PROC yields 198.02% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROC wins by $112.67M in total portfolio value
10 years
PROC
PROC
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full PROC calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — PROC vs NOBL

📍 PROC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROCNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROC + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROC pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROC
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, PROC beats the other by $48,054,112.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROC + NOBL for your $10,000?

PROC: 50%NOBL: 50%
100% NOBL50/50100% PROC
Portfolio after 10yr
$56.36M
Annual income
$28,267,374.71/yr
Blended yield
50.16%
📊

Analyst Conviction Gap

Where Wall Street is split right now

PROC
Analyst Ratings
1
Hold
Consensus: Hold
Price Target
$10.00
+890.1% upside vs current
Range: $10.00 — $10.00
Altman Z
0.9
Piotroski
5/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROC buys
0
NOBL buys
0
No recent congressional trades found for PROC or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROCNOBL
Forward yield198.02%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$112.70M$22.9K
Annual income after 10y$56,534,499.65$249.78
Total dividends collected$106.15M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PROC vs NOBL ($10,000, DRIP)

YearPROC PortfolioPROC Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$30,502$19,801.98$10,917$217.08+$19.6KPROC
2$89,086$56,448.56$11,903$221.48+$77.2KPROC
3$249,403$154,080.96$12,962$225.68+$236.4KPROC
4$670,003$403,142.26$14,099$229.68+$655.9KPROC
5$1,729,066$1,012,162.66$15,319$233.49+$1.71MPROC
6$4,291,289$2,441,188.37$16,628$237.10+$4.27MPROC
7$10,253,990$5,662,310.92$18,033$240.53+$10.24MPROC
8$23,616,660$12,644,890.45$19,539$243.78+$23.60MPROC
9$52,487,868$27,218,041.68$21,154$246.86+$52.47MPROC
10$112,696,518$56,534,499.65$22,884$249.78+$112.67MPROC

PROC vs NOBL: Complete Analysis 2026

PROCStock

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Full PROC Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this PROC vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROC vs SCHDPROC vs JEPIPROC vs OPROC vs KOPROC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.